Skip to main content

Table 2 Details of the selected studies

From: Needle tract seeding and abdominal recurrence following pre-treatment biopsy of gastrointestinal stromal tumors (GIST): results of a systematic review

First author and year of publication

Houdt 2021 [54]

Akahoshi 2014 [56]

Eriksson 2016 [55]

Study type

Retrospective analysis of two prospectively kept databases

Retrospective analysis of one prospectively kept database

Posthoc analysis of a randomized trial

Aim of the study

to evaluate local recurrence free survival and disease specific survival of GIST patients with or without pretreatment biopsy

To define diagnostic accuracy and safety of and tumor recurrence after EUS-FNA of gastric GIST

To evaluate if percutaneous tumor biopsy has an impact on RFS and OS in patients with GIST receiving adjuvant imatinib after tumor resection

Number of patients

228

44

389

Risk of recurrence (low, intermediate, high)

86, 43, 80, (19 unknown)

33, 10, 0

0, 0, 389

Patients with (neo-) adjuvant imatinib

Neoadjuvant 100 adjuvant 158

0

Adjuvant 389

Patients with biopsy

186

44

47

Biopsy technique

CNB = 166, FNA = 20, Transcutaneous = 70, Endoluminal = 116

EUS-FNA = 44

CNB = 33, FNA = 22,

CNB and FNA = 8

Complications of biopsy

N/A

0

N/A

Number of correct diagnoses from pretreatment biopsies

N/A

32

N/A

Recurrence related to biopsy

1

0

N/Ab

Total number of abdominal wall or peritoneal recurrences

25

0

N/Ab

Follow-up (months)

Median = 53

Mean = 35,

range = 2–108

Median = 54a

  1. aMedian follow-up was not reported in the manuscript of Eriksson et al. We report median follow-up as reported in the primary publication of the trial [55]
  2. bOnly recurrence free survival (RFS) and overall survival (OS) presented